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• ASD subjects present deficits in social, sensory and stereotyped behaviors;  
• Purinergic signaling is pivotal in modulating behavioral sets;  
• VPA-prenatal exposed animals showed purinergic-related molecular 
alterations; 
• Suramin rescued ASD impairments in VPA-animal model; 





Autism spectrum disorder (ASD) is characterized by deficits in communication and 
social interaction, restricted interests, and stereotyped behavior. Environmental 
factors, such as prenatal exposure to valproic acid (VPA), may contribute to the 
increased risk of ASD. Since disturbed functioning of the purinergic system has been 
associated with the onset of ASD and used as a potential therapeutic target for ASD 
in both clinical and preclinical studies, we analyzed the effects of suramin, a non-
selective purinergic antagonist, on behavioral, molecular and immunological in an 
animal model of autism induced by prenatal exposure to VPA. Treatment with 
suramin (20 mg/Kg, intraperitoneal) restored sociability in the three-chamber 
apparatus and decreased anxiety measured by elevated plus maze apparatus, but 
had no impact on decreased reciprocal social interactions or higher nociceptive 
threshold in VPA rats. Suramin treatment had no impact on VPA-induced 
upregulation of P2X4 and P2Y2 in hippocampus, and P2X4 in medial prefrontal 
cortex, but normalized an increased level of interleukin 6 (IL-6). Our results suggest 
an important role of purinergic modulation in behavioral, molecular, and 
immunological aberrations described in VPA model, and suggest that purinergic 
system might be a potential target for pharmacotherapy in preclinical studies of ASD. 
 




Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder 
characterized by impairments in communication and social interaction and repetitive 
or stereotyped behaviors (American Psychiatric Association, 2013). In the last years, 
the prevalence of ASD had a strong elevation (1:59 live births according to the most 
recent data from USA) (Baio et al., 2018), explained only in part by the changes in 
diagnostic parameters of DSM-5, demonstrating the necessity to expand studies in 
order to understand the pathways and possible risk factors involved in this disorder. 
Although the etiology is still unclear, it is already known that genetic and 
environmental factors are determinant for shaping the heterogeneous phenotypes 
exhibited by individuals with ASD (Chaste and Leboyer, 2012). The inflammatory 
dysregulation might appear as a potential etiological factor in neurodevelopmental 
disorders (Boulanger-Bertolus et al., 2018), such as ASD (Elias et al., 2015). Several 
studies demonstrated that the use of valproic acid (VPA) - an anticonvulsant drug 
widely used in the treatment of epilepsy, migraine and mood instabilities - during 
pregnancy, especially in the first trimester, can significantly increase the risk of 
developing autism (Christensen et al., 2013; Williams et al., 2001).  
Prenatal exposure to VPA is one of the best characterized rodent models of 
autism with strong construct, face, and predictive validity (Mabunga et al., 2015; 
Roullet et al., 2013). Male offspring of dams injected with VPA on E12,5 show 
autistic-like brain abnormalities and a plethora of behavioral aberrations including 
decreased social behavior (Bambini-Junior et al., 2011), hyperactivity and 
stereotypies (Schneider and Przewłocki, 2005), increased anxiety, lower sensitivity 
to pain and diminished acoustic prepulse inhibition (Schneider and Przewłocki, 
2005), resembling both core symptoms (Schneider and Przewłocki, 2005) and the 
most significant neurobehavioral derangements observed in autism (Fontes-Dutra et 
al., 2018; Lin et al., 2013; Markram et al., 2008). VPA offspring express also 
molecular and immunological aberrations including altered functioning of opioidergic 
(Schneider et al., 2007), serotonergic (Tsujino et al., 2007), dopaminergic (Nakasato 
et al., 2008), GABAergic (Robertson et al., 2016) and glutamatergic (Horder et al., 
2018) systems, decreased cellular immunity (Gottfried et al., 2015), 
electrophysiological impairments (Gogolla et al., 2009) and cytoarchitecture 
disruptions (Casanova et al., 2002; Fontes-Dutra et al., 2018; Hutsler and Casanova, 
2016). Thus, it became necessary to understand how VPA induces developmental 
alterations that lead to ASD analyzing, for example, modulation of different 
components of synaptic transmission, like the purinergic system.  
Several studies have demonstrated mitochondrial dysfunctions in ASD 
(Filipek et al., 2003; Patowary et al., 2017). This impairment of mitochondrial 
energetic metabolism and consequent increase in extracellular ATP levels (Faas et 
al., 2017) leads to the onset of inflammatory processes via purinergic signaling, 
suggesting that this system may be involved in the etiology of ASD. Experimental 
evidence indicate the participation of ATP-activated P2X and P2Y purinergic 
receptors in embryonic brain development as well as in adult neurogenesis for 
maintenance of normal brain functions (Glaser et al., 2013; Oliveira and Ulrich, 2016; 
Ulrich et al., 2012) and alterations in this context have been already related to 
psychiatric disorders, like autism (Cheffer et al., 2018). Previous studies 
demonstrated that suramin, a non-selective inhibitor of the purinergic system, has 
therapeutic effects on autistic-like behaviors in the animal model of autism through 
maternal immune activation (MIA) (Naviaux et al., 2014, 2013). Studies have shown 
that purinergic system could prevent behavioral changes in this animal model, which 
seem to be related with elevated levels of interleukin 6 (IL-6)(Smith et al., 2007). 
Interestingly, the Naviaux´s group recently demonstrated in a small, phase I/II, 
randomized clinical trial that a single intravenous dose of suramin was associated 
with improved scores for language, social interaction, and decreased restricted or 
repetitive behaviors. The five children who received placebo had no improvements 
these parameters (Naviaux et al., 2017). However, it is still unclear how the 
inflammatory response and the purinergic system is being modulated by both 
prenatal effect by VPA and post-natal treatment with the anti-purinergic suramin. 
Based on these previous findings, the aim of this work was to evaluate the 
therapeutic effects of suramin on several behaviors in an animal model of autism 
induced by prenatal exposure to VPA and elucidate the role of purinergic signaling 
on inflammatory responses in autism context. 
2. METHODS 
2.1. Animals and ethics 
Wistar rats obtained from the local breeding colony (ICBS-Federal University of 
Rio Grande do Sul) were maintained under standard laboratory conditions. The 
animals were mated overnight, and when pregnancy was established by the 
presence of spermatozoa in the vaginal smear, this day was considered the zero 
embryonic day (E0). The offspring was weaned at postnatal day 21 (P21) and only 
male animals were used in this study (Bambini-Junior et al., 2011). This project was 
approved by the local animal ethics committee (CEUA-UFRGS 23884) and all 
procedures were approved by the Institutional Ethics Committee on Animal Use in 
accordance with Brazilian Law 11794/2008 (Arouca Law) and National Institutes of 
Health guide for the care and use of Laboratory animals (NIH Publications No. 
8023). 
2.2. Treatments 
Valproic acid (sodium valproate, Sigma-Aldrich, USA) was dissolved in 0.9% 
saline to a final concentration of 250 mg/mL. Pregnant females received a single 
intraperitoneal injection of 600 mg/kg VPA or physiological saline on E12.5. Male 
offspring received a single intraperitoneal injection of suramin (hexasodium salt, 
Sigma-Aldrich, USA) at 20 mg/kg or its vehicle 0.1M PBS on P30. Thus, four 
experimental groups were formed: Control (only vehicles injected), suramin (SUR), 
VPA and VPA + SUR. The litters were split equally among the experimental groups 
proposed by the present work as it follows: if the litter size presented an even 
number, half received suramin treatment and the other half, PBS treatment. If the 
litter size presented an odd number, for example, the size of three, two rats received 
suramin treatment and one rat received PBS treatment, and vice versa, randomly. 
2.3. Behavioral tests 
Behavioral testing was performed in offspring, between P32-P40, starting two 
days after the injection of suramin. All behavioral tests were performed under light 
conditions of 60 LUX by experienced researchers using a double-blind approach. 
The following behavioral tests were performed: elevated plus maze, open 
field/grooming, whisker nuisance task (WNT), three-chambered test, reciprocal 
sociability test and tail flick test. Except for the WNT and tail flick, all tests were 
videotaped for later evaluations. 
2.3.1. Elevated Plus Maze (P32): The anxiety-like behavior was assessed in 
an elevated plus maze apparatus with a 10 cm × 10 cm center, 
connecting two opposite open arms (length: 50 cm) and two opposite 
arms closed with 30 cm high walls (length: 50 cm), 1 m above the floor. 
Rats were placed in the middle of apparatus and its movements were 
recorded for 5 minutes using a camera connected to a laptop. The time 
spent in the closed arms is considered a measure of anxious behavior. 
2.3.2. Open Field Test/Self-Grooming (P33): Adapted from Schneider and 
colleagues (Schneider and Przewłocki, 2005), the exploratory and 
locomotor activity and the time and number of stereotyped movements 
(self-grooming behavior) were assessed in an open field arena, which 
consists of a wooden box measuring 50x50x50 cm. Rats were placed in 
the center of the arena and recorded during 30 minutes. Using the 
Anymaze Software®, we performed a tracking of locomotor activity 
(travelled distance and average speed) and time spent and number of 
entries in the central during the 30 minutes of test.  
The self-grooming behavior was evaluated considering three different 
time periods (0-5, 10-15 and 20-25 minutes). We considered grooming 
as number of body cleaning with paws and face-washing actions and 
distinguished between complete (cleaning from snout to tail) and 
incomplete (fast and repetitive movements on snout) self-grooming. 
2.3.3. Whisker Nuisance Task (P34-35): Adapted from McNamara et al 
(McNamara et al., 2010) and described by Fontes-Dutra and colleagues 
(Fontes-Dutra et al., 2018), in this test we observed the animal response 
to the vibrissae stimulation. One day prior to test, animals were set to the 
experimenter for 5 minutes, in an empty housing (57.1 × 39.4 x 15.2 cm) 
coated with an absorbent pad. On the day of test, the vibrissae were 
stimulated with a wooden toothpick for three consecutive periods of 5 
min (15 min in total) with a 30 seconds interval between them. 
McNamara et al. (2010) developed a nonparametric scale of 0 to 2 
according to the response (0 = absent/typical, 1 = present/light response 
and 2 = profound/accentuated response), distributed in 8 categories of 
behavior: freezing, stance and body position, breathing, whisker position, 
whisking response, evading stimulation, response to stick presentation 
and grooming (McNamara et al., 2010). The maximum test score is 16. 
High scores (8-16) indicate abnormal responses to stimulation, in which 
the animal freezes, shakes, or is aggressive. The low scores (0-4) 
indicate normal responses, in which the rat is calm or indifferent to 
stimulation.  
2.3.4. Three-Chamber Test (P36-37): This test was performed as previously 
described by Bambini-Junior and colleagues (Bambini-Junior et al., 
2011). Briefly, at the beginning, the animal was habituated in the central 
chamber of the apparatus for 5 minutes. In the Sociability Test, one 
object was placed in one of the side chambers and in the other an 
unknown interaction animal (novel rat 1). We measured the time spent in 
each chamber and the time of exploration of either the rat or the object 
for 10 minutes.  
In the Social Novelty Test, the novel rat 1 (now known rat) remained in 
this place and an unknown rat (novel rat 2 – an unfamiliar and younger 
21-28 days old Wistar rat) was placed in the previously empty chamber. 
The time spent in each chamber and the time of exploration of both the 
rat known or not was also evaluated for 10 minutes.  
2.3.5. Reciprocal Social Behavior (P38): Adapted from Schneider et al. 
(Schneider and Przewłocki, 2005), the test was performed in the same 
box as the open field test during 15 minutes. The test animal was placed 
in the apparatus and, after a habituation period of 5 minutes, an 
unfamiliar and younger Wistar rat (21-28 days old) interaction animal 
was placed with the test animal. We evaluated the social behavior of the 
test animal using time and number of nose to nose interaction, 
anogenital inspection, flank exploration and following.  
2.3.6. Tail Flick (P39-40): Nociceptive thresholds were evaluated using a tail 
flick analgesimeter (Insight Equipments, Ribeirão Preto, Brazil). One day 
prior the test, the animals were gently restrained by hand for 5 minutes 
in order to habituate to apparatus. Tail flick measurements were taken 
three times at 30-seconds intervals.  
2.4. Tissue samples 
The animals were deeply anesthetized on P41 with ketamine (300 mg/Kg) 
and xilazine (40 mg/Kg). After, the animals were decapitated, and the medial 
prefrontal cortex and hippocampus were dissected. The tissues were immediately 
homogenized in TRIzol® reagent (Invitrogen, USA) and preserved at ultra-freezer 
until posterior molecular analysis. 
2.4.1. RNA Extraction and RT-qPCR Procedure: After homogenization of 
tissues samples, chloroform was added to perform phase separation, 
and RNA was precipitated from the upper aqueous layer using 
isopropanol. The precipitated RNA was washed with ethanol to remove 
impurities, resuspended in RNase-free water and stored at ultra-freezer 
(Hummon et al., 2007).  
The mRNA transcription levels of purinergic receptors and cytokines 
were evaluated by reverse transcriptase followed by quantitative 
polymerase chain reaction (RT-qPCR). Complementary DNA (cDNA) 
was synthesized from mRNA using reverse transcriptase reaction 
containing 2 µg of total RNA, 1 µL of 10 mM dNTP mix (Invitrogen, 
USA), 1 µL of oligodT primer, 4 µL M-MLV reverse transcriptase 5X 
reaction buffer (Invitrogen, USA), 2 µL of 0.1 M DTT (Invitrogen, USA), 1 
µL of RNase inhibitor (Invitrogen, USA), 1.0 µL of M-MLV reverse 
transcriptase (Invitrogen, USA), and sterile distilled water to a final 
volume of 20 µL. The synthesis of the cDNA was completed after a 
sequence of three incubations at 65ºC for 5 min, 37ºC for 50 min and 
70ºC for 15 min. 
The quantitative PCR mix was comprised by 8 µL of cDNA (1:40) and 12 
µL reaction mix containing  0.5 µL of 10 µM dNTP mix (Invitrogen, USA), 
2.0 µL of 10X PCR buffer (Invitrogen, USA), 0.8 µL of 50 mM MgCl2 
(Invitrogen, USA), 2.0 µL of 1X SYBRTM Green (Molecular Probes, 
USA), 0.1 µL of Platinum Taq DNA Polymerase (Invitrogen, USA), 0.2 
µL of specific forward and reverse (10 µM) primers (as specified in 
Supplementary Table 1) and sterile distilled water to a final volume of 20 
µL. The fluorescence of SYBRTM Green was used to detect amplification, 
estimate Ct values, and to determine specificity after melting curve 
analysis. PCR cycling conditions were standardized to 95ºC for 5 min 
followed by 40 cycles at 95ºC for 10 s, 58ºC for 10 s, and 72ºC for 10 s. 
After the main amplification, sample fluorescence was measured from 
60ºC to 95ºC, with an increasing ramp of 0.3ºC each, to obtain the 
denaturing curve of the amplified products and Tm estimation, to assure 
their homogeneity after peak detection. Data was obtained from an 
Applied Biosystems StepOne System (USA). 
The RT-qPCR results were imported into Microsoft Excel and the 
geNorm program was used to assess the variance in expression levels 
of the mRNA analyzed (Vandesompele et al., 2002). This program 
scanned all mRNA evaluated and ranked accordingly to their stability. 
The more stable mRNAs were used as endogenous expression controls. 
PCR efficiency was calculated from the slope of the amplification curve 
by exponential amplification analysis using the LinRegPCR algorithm 
(Ramakers et al., 2003). The relative expression of mRNA was 
calculated considering the 100 % PCR efficiency and the –∆∆Ct values 
for each mRNA (Livak and Schmittgen, 2001) and were normalized to 
the housekeeping genes identified by the geNorm software. 
2.5. Statistical analysis 
IBM SPSS Statistics 20.0 (IBM SPSS, Armonk, NY, USA) was used to 
perform the statistical analysis. Kolgomorov-Smirnov and Shapiro-Wilk tests of 
normality were applied to determine data distribution. For behavioral tests, we used 
Generalized Estimating Equations (GEE) to weight both the interventions (VPA 
exposure and/or suramin treatment) and the litter effect in the behavioral outcome. 
Considering that GEE is a flexible method based on general linear models, allowing 
the analysis of data with different distribution patterns, this protocol was utilized to 
compare different correlated variables (Fontes-Dutra et al., 2019). We also divided 
the litter equally among the experimental groups. After a Wald Chi-Square test, we 
performed pairwise comparisons for the parameters that presented interaction effect 
between interventions (VPA-by-suramin interaction). If only main effects were 
observed, the individual effect of VPA or suramin was evaluated. Bonferroni’s post 
hoc test was used as the final evaluation. Data is reported as mean ± standard error 
of the mean (SEM). The Poisson distribution was used for discrete variables 
(number), while gamma distribution was used for time variables.  
The relative expressions of purinergic receptors and cytokines were 
compared using one-way ANOVA followed by Bonferroni. The results were 
expressed as mean ± SEM. All statistical analyzes were supervised by the 
Biostatistics Unit at the Clinical Hospital of Porto Alegre. 
3. RESULTS 
3.1. Behavioral tests 
3.1.1. Social behavior analysis in the three-chambered test: Rats from control 
and suramin group spent significantly more time in the chamber 
containing a conspecific novel rat than a novel object (CON: p< 0.001; 
SUR: p=0.025; Figure 1A). In contrast, VPA animals did not present 
preference between spending time in the chamber with a rat or an object 
(p=0.550). Interestingly, suramin treatment of VPA-exposed rats was 
able to reestablish the social feature, as the VPA+SUR group showed 
preference to stay in the chamber together with the novel rat (p<0.001). 
Concerning social interaction, rats from both control and suramin groups 
also spent significantly more time exploring the cage containing the 
conspecific rather than the object (CON: p<0.001 SUR: p<0.001), while 
the VPA group showed no preference between rat and object exploration 
(p=0.131, Figure 1A). Suramin treatment was again able to restore this 
social behavior (VPA+SUR: p<0.001). 
In the test for social novelty, all groups showed no significant difference 
between the time spent in the novel rat chamber and the known rat 
chamber (CON: p=0.562; SUR: p=0.760; VPA: p=1.000; VPA+SUR: 
p=0.235; Figure 1B). However, rats from control and suramin groups 
spent significantly more time exploring the novel rat than the known rat 
(CON: p=0.003; SUR: p=0.005, Figure 1B), indicating an interest in 
social novelty. VPA rats did not show preference in exploration time 
between novel and known rat (VPA: p=0.13), whilst suramin treatment 
was able to prevent this social impairment in VPA-exposed animals 
(VPA+SUR: p=0.016, Figure 1B). 
3.1.2. Reciprocal social behavior: Prenatal exposure to VPA significantly 
reduced every reciprocal social interaction parameter evaluated, except 
for following behavior (Supplementary Figure S1). We observed only a 
VPA effect on total reciprocal social behavior, since VPA-exposed 
animals presented a decrease in number (p<0.001) and time (p<0.001) 
of social approaches and suramin treatment was not able to rescue 
these impairments (Figure 1C). 
3.1.3. Anxiety-like, exploratory and locomotor behavior: Rats from VPA group 
spent significantly less time exploring the open arm of the elevated plus-
maze apparatus, compared to animals from control (p=0.001) and 
suramin (p=0.003) groups. VPA+SUR group spent more time exploring 
the open arm of the apparatus compared to the VPA group (p<0.001; 
Figure 2A), indicating that suramin was able to rescue the anxiety-like 
behaviors in rats exposed to VPA. It is worth to note that no differences 
were found among experimental groups in open arms entries (all 
p>0.570; Supplementary Figure S2A) and number of risk assessments 
in the elevated plus-maze apparatus (all p>0.210; Supplementary Figure 
S2B). In the open field arena, animals from VPA group spent 
significantly less time in central square compared to animals from control 
(p=0.007) and suramin (p<0.001) groups. As observed in plus maze 
evaluation, suramin was able to rescue this alteration, since VPA+SUR 
group spent more time in central square compared to VPA group 
(p=0.004, Figure 2B). 
Concerning the exploratory behavior, only the VPA-exposed rats 
presented lower number of rearing in an open field arena (p=0.041, 
Figure 2C). Finally, when locomotor activity of those rats in the open field 
arena was evaluated, no significant differences in distance traveled (all 
p>0.910, Figure 2D) and average speed (all p>0.960, Supplementary 
Figure S2D) were found among experimental groups. 
3.1.4. Self-grooming behavior: The self-grooming behavior was evaluated 
across three testing periods (0-5, 10-15 and 20-25 minutes) and 
distinguished between complete and incomplete self-grooming. During 
the second period, VPA groups spent more time performing complete 
self-grooming compared to control animals (p=0.039), and suramin was 
not able to rescue from this altered behavior. Similarly, in the third 
period, the same pattern was observed in VPA animals (p=0.003, Table 
1). Taking all periods together, VPA-exposed animals spent more time 
doing complete self-grooming with no reversion by suramin treatment in 
this behavior (p=0.002, Figure 3A).  
Regarding to the time spent doing incomplete self-grooming, no 
difference was observed among the groups (all p>0.100, Table 1 or 
p>0.420, Figure 3C). However, the VPA group presented a trend to 
spend more time self-grooming in 10-15 min (p=0.065), a significant 
increase in the third period (p= 0.013, Table 1), considering the three 
periods of test (p=0.002, Figure 3E). In all cases, postnatal treatment 
with suramin was not able to rescue from these alterations. 
Concerning the number of self-grooming events, VPA animals presented 
more events of complete self-grooming only in the third period (p=0.002, 
Table 1) with a trend to increased total complete self-grooming (p=0.088, 
Figure 3B). When considered the number of incomplete self-grooming 
and all grooming events, no differences were observed among groups in 
the three periods analyzed (all p>0.210, Table 1) or considering three 
periods together (all p>0.553, Figure 3D). Finally, when considered the 
number of all events of self-grooming, VPA-exposed animals presented 
an increase only following 20-25 minutes (p=0.005, Table 1) with no 
differences in the total period of test (all p>0.130, Figure 3F).  
3.1.5. Sensory Behavior: In the whisker nuisance task (WNT), VPA-exposed 
animals presented a significant increased score when compared to 
control animals (p=0.001, Figure 4A), indicating higher levels of 
nuisance when whiskers are stimulated. The postnatal treatment with 
suramin was not able to rescue this alteration.  
Only a VPA effect was observed in the latency to tail withdrawal in 
nociceptive tail flick test, so that VPA-exposed animals presented higher 
latencies compared to non-exposed animals (p=0.012, Figure 4B). 
3.2. Molecular analysis 
3.2.1. Expression of purinergic receptors: The relative expression of mRNA 
was performed in the medial prefrontal cortex. GeNorm algorithm ranked 
P2Y2 and P2Y4 as most stable and they were used as housekeeping to 
evaluate the relative expression of the remaining receptors. The 
expression rate of the ionotropic receptor P2X4 was significantly 
increased in the cortex of animals prenatally exposed to VPA and 
suramin was not able to revert this alteration (F (3, 28) =11,98; 
p<0.0001) (Figure 5A). On the other hand, there were no significant 
differences in levels of remaining receptors (Figure 5A). 
When the receptors were evaluated in hippocampus of the young rats, 
P2X3 and P2Y4 were used as housekeeping. Curiously, the ionotropic 
receptor P2X4 was found significantly increased in animals from VPA 
and VPA+SUR groups, compared to control group also in this region (F 
(3, 28)=6,020; p=0.0027).  Additionally, animals presented increased 
mRNA levels coding for metabotropic receptor P2Y2 in VPA and 
VPA+SUR group compared to control group (F (3, 28) =6,194; 
p=0.0023). In both cases, suramin was not able to reverse this alteration 
(Figure 5B). Nevertheless, levels of remaining purinergic receptors 
showed no differences among experimental groups (Figure 5B). 
3.2.2. Expression of cytokine mRNA levels: In the medial prefrontal cortex, 
considering GAPDH and Beta3-tubulin as housekeeping genes, the 
animals from VPA group presented an increase in relative expression of 
IL-6 mRNA compared to control group (F (3, 24)=5,406; p=0.005) and 
the postnatal treatment with suramin rescued the levels of IL-6 of VPA-
exposed rats to control levels (Figure 6A). On the other hand, IL-1β, IFN-
γ and TNF-α showed no differences between groups. Regarding to 
hippocampus and considering the same housekeeping mRNA, no 
differences were found in cytokine levels among all experimental groups 
(Figure 6B).  
 
4. DISCUSSION 
An important approach in VPA model is the possibility of developing 
therapeutic strategies to attenuate several features observed in ASD. For instance, 
our group demonstrated that resveratrol (RSV), an antioxidant and anti-inflammatory 
molecule, prevents VPA-induced social impairments in the three-chamber test 
(Bambini-Junior et al., 2014) and in the number and time of reciprocal social 
interactions (Hirsch et al., 2018). The present results corroborate impairments in 
sociability and social novelty exploration in the three-chamber test, as previously 
demonstrated (Bambini-Junior et al., 2014, 2011). As previously shown, the 
postnatal treatment with a single dose of suramin was able to rescue social 
impairments (Naviaux et al., 2014).  It is important to consider that there could be 
different schedules of administration of suramin, but considering its half-life and 
relevant clinical data, here we employed a single dose of antipurinergic treatment. 
Additionally, the decrease in total reciprocal social interaction was not 
reversed by suramin. In fact, the reciprocal social behavior test involves complex 
patterns of socialization between two free animals, unlike the three-chamber test, 
where the conspecific animal remains trapped in a cage. Therefore, this 
characteristic of the test could be forcing the analyzed animal towards more complex 
social behavior actions, possibly causing additional impairments not reversed by 
suramin. 
Another main finding of our study was that VPA rats presented a more 
anxious-like behavior compared to control animals as seen in plus maze apparatus 
and open field arena. Anxiety behavior is one of most common comorbidities in ASD 
and has been reported to be present in around 50% of autistic children and 
adolescents (Simonoff et al., 2008; van Steensel et al., 2011). Our study 
corroborates previous studies that demonstrated increased anxiety-like behavior in 
animal models of autism (Patterson, 2011). Interestingly, the treatment with suramin 
was able to rescue completely this alteration, which was seen by the higher 
percentage of total time spent exploring the open arm of the apparatus compared to 
VPA group.  
We also observed that VPA-exposed animals do not present significant motor 
alterations or hyperactivity, but demonstrated a significant reduction in vertical 
exploratory activity, which could be related to the reduction in social interest of VPA 
animals described in sociability test, since animals with less exploratory tendencies 
possibly have impairments related to social approach. As observed in reciprocal 
sociability test, the postnatal treatment with suramin was not able to rescue the 
impairments observed in this exploratory behavior.  
In addition to analyzing social behavior, the present study also assessed 
another core symptom of autism - the repetitive and stereotyped behavior. In animal 
models of autism, this feature can be measured by analyzing the repetitive self-
grooming behavior. In present work, we assessed separately the self-grooming 
behavior as complete and incomplete events. The VPA-exposed animals showed 
increased time of complete self-grooming, without alteration in both number and time 
of incomplete grooming. Studies have demonstrated that only complete grooming is 
initiated by cerebellar midline or locus coeruleus stimulation (Strazielle et al., 2012) 
and that ATP can induce depolarization and increase excitability of 
norepinephrinergic system from locus coeruleus, possibly mediated by specific 
modulators of P2 receptors (Masaki et al., 2001; Yao and Lawrence, 2005), 
suggesting a putative role of purinergic system in grooming outcomes.  
Previous studies already demonstrated that grooming behavior could be 
related to sensory components (Houghton et al., 2018). Corroborating a previous 
work from our group (Fontes-Dutra et al., 2018), we observed that VPA animals 
presented hypersensitivity to a non-harmful stimulus in WNT, suggesting a 
disturbance in sensory gating which could lead to increase in self-grooming 
behavior.  Hyposensitivity to pain is also frequently observed in autistic subjects, 
although this feature is not a consensus, since different findings were observed 
depending on how the studies were conducted (Moore, 2015). In our study, VPA-
exposed rats presented higher latencies to sense a thermal stimulus, indicating a 
lower nociceptive reactivity in accordance to previous work (Schneider et al., 2008). 
Postnatal treatment with suramin was not able to rescue these sensorial impairments 
in VPA animals. Taking together, in the present work we demonstrated that VPA-
induced alterations in behavioral components related to social and anxiety behavior 
in the animal model of ASD can be modulated by the anti-purinergic molecule 
suramin, highlighting the role of purinergic system in the pathophysiology of ASD. 
There are only a few studies in literature indicating the roles of purinergic 
system in sensory processing. Nevertheless, it is known that purinergic system plays 
important roles in sensory pathways (Irnich et al., 2002). Our data presented 
increased expression of cortical heteromeric P2X4 receptor in VPA-exposed 
animals. Since this receptor is involved with immunological responses in several 
tissues, the involvement of purinergic signaling in the ASD pathophysiology may be 
related to neuroimmunological alterations, as already found in patients (Gottfried et 
al., 2015) and animal models of autism (Wei et al., 2012; Xu et al., 2015). It is 
already known that suramin has therapeutic effects on social deficits (Naviaux et al., 
2014, 2013), although it is poorly able to cross the blood brain barrier (Hawking, 
1978; Roboz et al., 1998). Our hypothesis is that suramin could be acting only at 
peripheral levels and modulates some characteristics of autism, possibly through a 
crosstalk between immunological and central nervous systems of these animals. 
Our study demonstrated that animals from VPA group showed increased 
levels of pro-inflammatory cytokine IL-6 in medial prefrontal cortex. Interestingly, a 
remarkable finding in the present work was the restoration IL-6 levels in this area 
after treatment with suramin. Since the levels of this cytokine are commonly 
increased in autistic patients (Gottfried et al., 2015) and in animal models of autism 
(Wei et al., 2012; Xu et al., 2015), the suramin-induced effect on IL-6 levels could 
play a role on its changes in social and anxiety-like behavior (Xu et al., 2015), which 
also has been rescued by suramin treatment. Therefore, the present data contribute 
to the understanding of how purinergic system is being modulated in VPA animal 
model of ASD, elucidating important VPA-induced alterations in ASD-related 
behaviors, changing both the expression pattern of purinergic receptors in medial 
prefrontal cortex and hippocampus, and the levels of IL-6, potentially pointing to 
roles in purinergic system and inflammation status in VPA animal model. By contrast, 
postnatal treatment by suramin was capable to prevent alterations in social and 
anxiety-like behavior induced by VPA prenatal exposure, concomitantly reverting the 
levels of IL-6 in the same model. 
 
5. CONCLUSION 
In summary, our findings reinforce the idea of antipurinergic therapy as a 
novel pharmacological target in disorders associated with inflammatory 
dysregulation, including autism and provide new insights for the development of 
effective and safe treatments. Although VPA-exposed animals seem to present 
higher permeability in blood-brain barrier (Kumar et al., 2015; Kumar and Sharma, 
2016a, 2016b), the limited access of suramin to CNS could explain the limitations of 
suramin-based therapeutic strategies. Even though suramin has been used in 
humans for more than 100 years as a therapeutic agent, it has plethora of important 
dose-dependent side effects. However, the present data provide remarkable support 
for the hypothesis that a drug acting through peripheral immune and inflammatory 
components can modulate some molecular and behavioral alterations in VPA autism 
model. As pointed out in a recent review (Burnstock, 2018), the development of 
purinergic compounds for the treatment of a wide variety of diseases is still in its 
infancy, but for sure, suramin studies open an important window for new drug 
designs and therapies. Further studies are necessary to elucidate the mechanisms 
of suramin action. In addition to this, the use of some specific and safer drugs could 
be more efficient to rescue autistic-related impairments. 
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LEGENDS OF FIGURES 
 
Figure 1. Social behavior in VPA autism model. (A) Time spent in chambers 
and interaction time in sociability (B), social novelty tests in a three-
chambered apparatus and (C) number and time of total pro-social interactions. 
Data expressed as means ± SEM. Asterisks indicate statistical differences with 
*p<0.05, **p<0.01, ***p<0.001. Statistical analysis: Generalized Estimating Equations 
(GEE) followed by Bonferroni. Three-chambered test: CON (n = 15), SUR (n = 15), 
VPA (n = 11), VPA+SUR (n = 13). Reciprocal interactions: CON (n = 18), SUR (n = 
16), VPA (n = 14), VPA+SUR (n = 13). 
  
Figure 2.  Anxiety, exploratory and locomotor behavior in VPA autism model. 
(A) Percent of time spent in the open arms in the elevated plus-maze; (B) Time 
spent in central square; (C) Number of rearings and (D) distance travelled in a 
50x50x50 open field arena. Data expressed as means ± SEM. Different letters 
indicate statistical differences with p<0.05 considered significant. Statistical analysis: 
Generalized Estimating Equations (GEE) followed by Bonferroni. Plus Maze: CON (n 
= 18), SUR (n = 16), VPA (n = 15), VPA+SUR (n = 15). Open Field: CON (n = 16), 
SUR (n = 15), VPA (n = 13), VPA+SUR (n = 14). 
  
Figure 3. Self-grooming behavior in VPA autism model. Time of (A) complete, 
(C) incomplete and (E) total grooming; Number of (B) complete, (D) incomplete 
and (F) total grooming. Data expressed as means ± SEM with **p<0.01 considered 
significant.. Statistical analysis: Generalized Estimating Equations (GEE) followed by 
Bonferroni. CON (n = 16), SUR (n = 15), VPA (n = 13), VPA+SUR (n = 14). 
 
Figure 4. Sensorial behavior in VPA autism model. (A) Total score in Whisker 
Nuisance Task and (B) latency to respond to thermal stimuli. Data expressed as 
means ± SEM with *p<0.05. Statistical analysis: Generalized Estimating Equations 
(GEE) followed by Bonferroni. WNT: CON (n = 15), SUR (n = 14), VPA (n = 13), 
VPA+SUR (n = 13). Tail flick: CON (n = 17), SUR (n = 14), VPA (n = 13), VPA+SUR 
(n = 14).  
  
Figure 5. Expression levels of purinergic receptors in medial prefrontal cortex 
(A) and hippocampus (B) of young rats from VPA autism model.  Plots 
presented as mean ± SEM with *p<0.05, **p<0.01, ***p<0.001. Statistical analysis: 
One-Way ANOVA followed by Tukey’s test. n = 8 for all groups in both tissues. 
 
Figure 6. Expression levels of pro-inflammatory cytokines in medial prefrontal 
cortex (A) and hippocampus (B) of young rats from VPA autism model. Results 
expressed as means ± SEM with *p <0.05 considered significant. Statistical analysis: 
One-Way ANOVA followed by Tukey’s test. nMPC = 6-8 and nHIP = 8 for all groups. 
  
Figure S1. Evaluation of individual reciprocal social interaction in VPA autism 
model. Counts and time of (A) nose-to-nose sniffing, (B) anogenital inspection, (C) 
flank exploration and (D) following. Data expressed as means ± SEM with *p <0.05 
considered significant, indicating a SUR per se effect. Statistical analysis: 
Generalized Estimating Equations (GEE) followed by Bonferroni. CON (n = 18), SUR 
(n = 16), VPA (n = 14), VPA+SUR (n = 13).  
 
Figure S2. Exploratory and locomotor behavior in VPA autism model. (A) Open 
arms entries and (B) Number of risk assessments in the elevated plus-maze 
apparatus; (C) average speed in a 50x50x50 cm open field arena. Data expressed 
as means ± SEM with *p <0.05. Statistical analysis: Generalized Estimating 
Equations (GEE) followed by Bonferroni. Plus Maze: CON (n = 18), SUR (n = 16), 
VPA (n = 15), VPA+SUR (n = 15). Open Field: CON (n = 16), SUR (n = 15), VPA (n 
= 13), VPA+SUR (n = 14).  
 
 
Table 1. Self-grooming behavior in VPA autism model. Time and number 
of complete, incomplete and total grooming in three different time ranges.  
 
Data expressed as means ± SEM. Different letters indicate statistical 
differences with p<0.05 considered significant between groups that received 
VPA (VPA and VPA+SUR) and groups that did not receive VPA (CON and 
SUR), indicating the effect of prenatal exposure to VPA. #tendency of difference 
significant among groups that received VPA or not (p = 0.065). Statistical 
analysis: Generalized Estimating Equations (GEE) followed by Bonferroni. CON 
(Control, n = 16), SUR (Suramin, n = 15), VPA (valproic acid, n = 13), 





















CON 0,98 ± 0,66 12,67 ± 3,39 a 14,08 ± 5,07 a 
SUR 1,39 ± 0,91 11,12 ± 4,01 a 10,66 ± 4,21 a 
VPA 0,01 ± 0,00 23,57 ± 6,79 b 33,29 ± 7,54 b 
VPA+SUR 0,29 ± 0,27 21,67 ± 5,83 b 30,06 ± 8,06 b 
Incomplete 
grooming 
CON 1,43 ± 0,55 1,52 ± 0,69 4,17 ± 1,71 
SUR 2,01 ± 1,03 2,72 ± 1,15 1,59 ± 0,86 
VPA 2,48 ± 1,12 2,26 ± 1,69 1,78 ± 0,94 




CON 2,41 ± 0,80 14,18 ± 3,95 a 18,24 ± 5,05 a 
SUR 3,40 ± 1,25 13,85 ± 4,33 a 12,25 ± 4,69 a 
VPA 2,49 ± 1,12 25,84 ± 7,94 # 35,07 ± 7,95 b 









CON 0,12 ± 0,08 1,25 ± 0,34 0,69 ± 0,17 a 
SUR 0,20 ± 0,14 1,33 ± 0,38 0,73 ± 0,27 a 
VPA 0,01 ± 0,00 1,08 ± 0,29 1,77 ± 0,45 b 
VPA+SUR 0,08 ± 0,07 1,62 ± 0,38 1,62 ± 0,32 b 
Incomplete 
grooming 
CON 0,38 ± 0,12 0,31 ± 0,12 0,44 ± 0,15 
SUR 0,27 ± 0,11 0,33 ± 0,12 0,27 ± 0,11 
VPA 0,46 ± 0,18 0,38 ± 0,23 0,31 ± 0,17 




CON 0,50 ± 0,15 1,56 ± 0,40 1,13 ± 0,23 a 
SUR 0,47 ± 0,16 1,67 ± 0,42 1,00 ± 0,36 a 
VPA 0,47 ± 0,16 1,46 ± 0,47 2,08 ± 0,47 b 
VPA+SUR 0,46 ± 0,14 1,77 ± 0,36 2,15 ± 0,37 b 






